 | • レポートコード：STR-DC037 • 出版社/出版日：Straits Research / 2019年11月28日 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：製薬 |
| Single User（1名様用、印刷不可） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User（5名様用） | ￥836,200 (USD5,650) | ▷ お問い合わせ |
| Enterprise Price（法人閲覧用） | ￥1,073,000 (USD7,250) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートでは、早期陣痛治療の世界市場について調査・分析し、調査手法、市場概要、薬物別（子宮収縮抑制薬、抗生物質ベータ模倣薬、コルチコステロイド、その他）分析、剤形別（錠剤＆カプセル剤、注射剤、その他）分析、エンドユーザー別（病院、老人ホーム、薬局）分析、地域別分析、企業概要などを含め次の構成でお届け致します。 ・イントロダクション ・調査手法 ・市場概要 ・早期陣痛治療の世界市場：薬物別（子宮収縮抑制薬、抗生物質ベータ模倣薬、コルチコステロイド、その他） ・早期陣痛治療の世界市場：剤形別（錠剤＆カプセル剤、注射剤、その他） ・早期陣痛治療の世界市場：エンドユーザー別（病院、老人ホーム、薬局） ・早期陣痛治療の世界市場：地域別 ・企業概要 |
Global preterm labor treatment market was valued at USD 760.8 million in 2018, growing at a CAGR of 5.1% during the forecast period of 2019–2026.
Preterm Labor Treatment is a medical condition resulting in uterus contraction which brings about the changes in cervix starting approximately 37 weeks before pregnancy. Dilation in which cervix opens up for the entry of fetus into birth canal and effacement in which cervix thins out, are the two changes which are adapted by the cervix in Preterm Labor Treatment. It is a condition of severe concern as the babies born in Preterm Labor Treatment are generally unhealthy or are born with some sort of disabilities which may last for lifetime. Prevalence of Preterm Labor Treatment is increasing across the globe owing to the changing lifestyle and changing eating and drinking habits.
Increasing Prevalence of Smoking and Alcohol Consumption
With the increasing hectic lifestyle and lifestyle related stress, women are becoming more prone to accept various means to release or relive stress. Today, a greater number of women across the globe are developing addiction for smoking and alcohol, especially in developed countries. The same trend is witnessed among pregnant women and its prevalence is increasing rapidly. In some studies, it has been found that the frequency of Preterm Labor Treatment is high among heavy and moderate smokers than normal individuals. For instance, according to the American Pregnancy Association, more than 1000 neonatal dies each year due to smoking in the U.S. and the number is likely to increase in the coming years.
Segmental Insights
For a better understanding of the global Preterm Labor Treatment market, we have segmented the market by drugs, dosage form and end user.
By drugs, the market is segmented into tocolytic drugs, antibiotics beta mimetic, corticosteroids, others. Tocolytic drugs is accounting for the 43.6% of the market. Tocolytic drugs are used to slow the uterine contractions and delay the delivery for a short time to buy some time for corticosteroids and magnesium sulfate treatment. Extended time also helps the patient to seek better treatment options, which is one of the major factors driving the demand for tocolytic drugs. Tocolytics are also used as a substitute for various drugs like salbutamol, which further supports the market growth. For Instance, in the U.S., the nifedipine (calcium channel blocker) is considered as the first line tocolytic drug with fewer side effects and perhaps a better safety profile compared to other agents.
Regional Insights
Global Preterm Labor Treatment market by Americas, Asia Pacific, Europe, and the Middle East and Africa.
North America is holding a considerable share of the global Preterm Labor Treatment treatment market. This can be attributed to moderate prevalence of premature birth, high healthcare expenditure, strong awareness among parents, huge women smoking population, and high acceptance of IVF. The U.S. has the huge smoking and alcohol consuming populations. In 2016, the prevalence of smoking was higher around 18.9% in mothers aged between 20 and 29, and 5.2% in mothers aged between 30 and 34. Moreover, about 10% pregnant women in the U.S. consume alcohol and about 1% women are occasional drinkers. With the rapid adoption of advanced technologies such as IVF in the region, the prevalence of premature birth has also increased along with several complications during pregnancy. To cover these complications, physician is prescribing a range of preterm medicines.
Europe is second leading region in the forecast period backed by increasing prevalence of smoking and premature birth, favorable government reimbursement policies, and strong penetration of IVF treatment. A significant number of preterm born children live with several disabilities affecting their physical and mental developments, which affect their families. Therefore, governments are running various campaigns through social media and constructive dialogue to create awareness about preterm birth and various measures to overcome the problem. Europe also has a huge woman smoking population. According to the NHS Digital, about 11% pregnant European women smoked during 2018–19, which increased the chances of preterm birth as well as market for its treatment options.
Middle East & Africa Preterm Labor Treatment market to witness exponential growth in the coming years as result of improving healthcare facilities and rising number of teenage mothers. Additionally, growing urbanization, improving healthcare infrastructure, and high disposable income in the Middle East countries such as the UAE, Saudi Arabia, and Kuwait to boost the market growth. In Africa, the prevalence of preterm birth is higher than the Middle East countries on account of teenage pregnancy, poor healthcare infrastructure, and a smaller number of health checkups during pregnancy. However, the University of California has taken initiates to reduce the preterm birth in East Africa by providing better healthcare facilities to mother and newborn during pregnancy.
Key Players
Some of the prominent players in the market are Merck & Co., Inc., Pfizer Inc, Novartis AG, Sanofi, AstraZeneca, GlaxoSmithKline plc. and Cipla Inc.
TABLE OF CONTENTS
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Market Overview
3.1 Report Segmentation & Scope
3.2 Value Chain Analysis: Preterm Labor Treatment Market
3.3 Key Market Trends
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitution
3.4.4 Threat of New Entrants
3.4.5 Competitive Rivalry
3.5 Market Share Analysis
4 Drugs Overview
4.1 Introduction
4.1.1 Market Size & Forecast
4.2 Tocolytic Drugs
4.3 Antibiotics Beta–Mimetic
4.4 Corticosteroids
4.5 Others
5 Dosage Form Overview
5.1 Introduction
5.1.1 Market Size & Forecast
5.2 Tablets & Capsules
5.3 Injection
5.4 Other
6 End User Overview
6.1 Introduction
6.1.1 Market Size & Forecast
6.2 Hospitals
6.3 Nursing Homes
6.4 Pharmacy
7 Regional Overview
7.1 Introduction
7.1.1 Market Size & Forecast
7.2 America
7.2.1 North America
7.2.1.1 U.S.
7.2.1.1.1 By Drugs
7.2.1.1.2 By Dosage Form
7.2.1.1.3 By End User
7.2.1.2 Canada
7.2.1.2.1 By Drugs
7.2.1.2.2 By Dosage Form
7.2.1.2.3 By End User
7.2.1.3 Mexico
7.2.1.3.1 By Drugs
7.2.1.3.2 By Dosage Form
7.2.1.3.3 By End User
7.2.2 South America
7.2.2.1 By Drugs
7.2.2.2 By Dosage Form
7.2.2.3 By End User
7.3 Europe
7.3.1 Market Size & Forecast (Value)
7.3.2 Western Europe
7.3.2.1 Germany
7.3.2.1.1 By Drugs
7.3.2.1.2 By Dosage Form
7.3.2.1.3 By End User
7.3.2.2 France
7.3.2.2.1 By Drugs
7.3.2.2.2 By Dosage Form
7.3.2.2.3 By End User
7.3.2.3 U.K.
7.3.2.3.1 By Drugs
7.3.2.3.2 By Dosage Form
7.3.2.3.3 By End User
7.3.2.4 Italy
7.3.2.4.1 By Drugs
7.3.2.4.2 By Dosage Form
7.3.2.4.3 By End User
7.3.2.5 Spain
7.3.2.5.1 By Drugs
7.3.2.5.2 By Dosage Form
7.3.2.5.3 By End User
7.3.2.6 Rest of Western Europe
7.3.2.6.1 By Drugs
7.3.2.6.2 By Dosage Form
7.3.2.6.3 By End User
7.3.3 Eastern Europe
7.4 Asia Pacific
7.4.1 Market Size & Forecast (Value)
7.4.2 China
7.4.2.1 By Drugs
7.4.2.2 By Dosage Form
7.4.2.3 By End User
7.4.3 India
7.4.3.1 By Drugs
7.4.3.2 By Dosage Form
7.4.3.3 By End User
7.4.4 Japan
7.4.4.1 By Drugs
7.4.4.2 By Dosage Form
7.4.4.3 By End User
7.4.5 South Korea
7.4.5.1 By Drugs
7.4.5.2 By Dosage Form
7.4.5.3 By End User
7.4.6 Australia
7.4.6.1 By Drugs
7.4.6.2 By Dosage Form
7.4.6.3 By End User
7.4.7 Rest of Asia-Pacific
7.4.7.1 By Drugs
7.4.7.2 By Dosage Form
7.4.7.3 By End User
7.5 Middle East
7.5.1 Market Size & Forecast (Value)
7.5.2 The Middle East
7.5.2.1 UAE
7.5.2.2.1 By Drugs
7.5.2.2.2 By Dosage Form
7.5.2.2.3 By End User
7.5.2.2 Qatar
7.5.2.2.1 By Drugs
7.5.2.2.2 By Dosage Form
7.5.2.2.3 By End User
7.5.2.3 Rest of Middle East
7.5.2.3.1 By Drugs
7.5.2.3 2 By Dosage Form
7.5.2.3 3 By End User
7.6 Africa
7.6.1 Market Size & Forecast (Value)
7.6.2 South Africa
7.6.2.1 South Africa
7.6.2.1.1 By Drugs
7.6.2.1.2 By Dosage Form
7.6.2.1.3 By End User
7.6.2.2 Ghana
7.6.2.2.1 By Drugs
7.6.2.2.2 By Dosage Form
7.6.2.2.3 By End User
7.6.2.3 Nigeria
7.6.2.3.1 By Drugs
7.6.2.3.2 By Dosage Form
7.6.2.3.3 By End User
7.6.2.4 Rest of Africa
7.6.2.4.1 By Drugs
7.6.2.4 2 By Dosage Form
7.6.2.4.3 By End User
8. Company Profile
8.1 Merck & Co., Inc
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Recent Developments
8.1.4 Product Portfolio
8.2 Pfizer Inc
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Recent Developments
8.2.4 Product Portfolio
8.3 Novartis AG
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Recent Developments
8.3.4 Product Portfolio
8.4 Sanofi
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Recent Developments
8.4.4 Product Portfolio
8.5 AstraZeneca
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Recent Developments
8.5.4 Product Portfolio
8.6 GlaxoSmithKline plc
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Recent Developments
8.6.4 Product Portfolio
8.7 Cipla Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Recent Developments
8.7.4 Product Portfolio
TABLE 1 Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 2 Tocolytic Drugs Preterm Labor Treatment Market Share, By Region, 2016-2026 ($ Million)
TABLE 3 Antibiotics Beta – Mimetic Preterm Labor Treatment Market Share, By Region, 2016-2026, ($ Million)
TABLE 4 Corticosteroids Preterm Labor Treatment Market Share, By Region, 2016-2026, ($ Million)
TABLE 5 Others Preterm Labor Treatment Market Share, By Region, 2016-2026, ($ Million)
TABLE 6 Preterm Labor Treatment Market Share Value, 2016-2026 ($Million)
TABLE 7 Preterm Labor Treatment Market Share, By Region, 2016-2026 ($ Million)
TABLE 8 America Preterm Labor Treatment Market Share Value, By Region, 2016-2026 ($Million)
TABLE 9 America Preterm Labor Treatment Market Share value, By Drugs, 2016-2026 ($Million)
TABLE 10 America Preterm Labor Treatment Market Share value, By End User, 2016-2026 ($Million)
TABLE 11 U.S. Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 12 U.S. Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 13 Canada Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 14 Canada Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 15 Mexico Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 16 Mexico Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 17 South America Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 18 South America Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 19 Europe Preterm Labor Treatment Market Share Value, By Region, 2016-2026 ($Million)
TABLE 20 Europe Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 21 Europe Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 22 Western Europe Preterm Labor Treatment Market Share Value, By Country, 2016-2026 ($Million)
TABLE 23 Western Europe Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 24 Western Europe Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 25 Germany Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 26 Germany Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 27 France Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 28 France Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 29 UK Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 30 UK Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 31 Italy Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 32 Italy Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 33 Spain Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 34 Spain Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 35 Rest of Western Europe Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 36 Rest of Western Europe Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 37 Eastern Europe Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 38 Eastern Europe Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 39 Asia-Pacific Preterm Labor Treatment Market Share, By Country, 2016-2026 ($Million)
TABLE 40 Asia-Pacific Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 41 Asia-Pacific Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 42 Japan Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 43 Japan Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 44 China Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 45 China Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 46 Australia Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 47 Australia Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 48 India Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 49 India Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 50 South Korea Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 51 South Korea Preterm Labor Treatment Market Share, By End User 2016-2026 ($Million)
TABLE 52 Rest of Asia-pacific Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 53 Rest of Asia-pacific Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 54 The Middle East and Africa Preterm Labor Treatment Market Share, By Region, 2016-2026 ($Million)
TABLE 55 The Middle East and Africa Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 56 The Middle East and Africa Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 57 The Middle East Preterm Labor Treatment Market Share, By Country, 2016-2026 ($Million)
TABLE 58 The Middle East Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 59 The Middle East Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 60 Saudi Arabia Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 61 Saudi Arabia Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 62 UAE Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 63 UAE Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 64 Qatar Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 65 Qatar Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
TABLE 66 Africa Preterm Labor Treatment Market Share, By Country, 2016-2026 ($Million)
TABLE 67 Africa Preterm Labor Treatment Market Share, By Drugs, 2016-2026 ($Million)
TABLE 68 Africa Preterm Labor Treatment Market Share, By End User, 2016-2026 ($Million)
List of Figures
FIGURE 1 Preterm Labor Treatment Market Overview
FIGURE 2 Value Chain Analysis
FIGURE 3 Bargaining Power of Suppliers
FIGURE 4 Bargaining Power of Buyers
FIGURE 5 Threat of Substitutes
FIGURE 6 Threat of New Entrants
FIGURE 7 Competitive Rivalry
FIGURE 8 Preterm Labor Treatment Market, 2016-2026
FIGURE 9 U.S. Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 10 Canada Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 11 Mexico Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 12 South America Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 13 Western Europe Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 14 Germany Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 15 France Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 16 UK Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 17 Italy Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 18 Spain Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 19 Rest of Western Europe Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 20 Eastern Europe Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 21 Japan Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 22 China Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 23 Australia Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 24 India Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 25 South Korea Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 26 Rest of Asia-pacific Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 27 The Middle East Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 28 Saudi Arabia Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 29 UAE Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 30 Qatar Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 31 Rest of The Middle East Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 32 Africa Preterm Labor Treatment Market Share, 2016-2026 ($Million)
FIGURE 33 Merck & Co., Inc: Revenue Analysis, ($ million)
FIGURE 34 Merck & Co., Inc: Segment Revenue 2018 (%)